Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
acute lymphoblastic leukemia
adult
inotuzumab ozogamicin
salvage therapy
sinusoidal obstruction syndrome
targeted therapy
veno‐occlusive disease
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
revised:
18
06
2024
received:
07
05
2024
accepted:
09
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
2
8
2024
Statut:
aheadofprint
Résumé
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Several clinical trials are investigating InO in combination with low-intensity chemotherapy or other anti-ALL-targeted therapies in the salvage and frontline settings, notably in older adults who often cannot tolerate intensive chemotherapy and tend to have higher-risk disease. InO is also increasingly used to bridge patients to hematopoietic stem cell transplantation (HSCT), in sequence with chimeric antigen receptor T-cell therapy, to eliminate measurable residual disease and to prevent post-HSCT relapse. Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer Inc.
Informations de copyright
© 2024 American Cancer Society.
Références
Terwilliger T, Abdul‐Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi:10.1038/bcj.2017.53
Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645‐1666. doi:10.1016/j.mayocp.2016.09.010
Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524‐2539. doi:10.3324/haematol.2020.247031
Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67‐75. doi:10.1200/jop.18.00271
Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: a population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980‐2017. Am J Hematol. 2021;96(6):650‐658. doi:10.1002/ajh.26156
Jammal N, Kantarjian HM, Haddad F, Jabbour EJ. Management of acute lymphoblastic leukemia in older adults. Clin Adv Hematol Oncol. 2022;20(3):161‐168.
Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies for adult patients with B‐lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):150. doi:10.1186/s13045‐017‐0516‐x
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944‐950. doi:10.1182/blood‐2006‐05‐018192
Oriol A, Vives S, Hernandez‐Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk‐adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589‐596. doi:10.3324/haematol.2009.014274
Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216‐1230. doi:10.1002/(sici)1097‐0142(19991001)86:7<1216::aid‐cncr17>3.0.co;2‐o
Hoelzer D, Bassan R, Boissel N, Roddie C, Ribera J, Jerkeman M. ESMO clinical practice guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Ann Oncol. 2024;35(1):15‐28. doi:10.1016/j.annonc.2023.09.3112
Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B‐cell acute lymphoblastic leukemia. Hematology. 2022;27(1):642‐652. doi:10.1080/16078454.2022.2074704
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740‐753. doi:10.1056/nejmoa1509277
DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody‐targeted chemotherapy with CMC‐544: a CD22‐targeted immunoconjugate of calicheamicin for the treatment of B‐lymphoid malignancies. Blood. 2004;103(5):1807‐1814. doi:10.1182/blood‐2003‐07‐2466
Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab‐ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 pt A):107‐116. doi:10.1016/j.molimm.2014.09.014
Pfizer Inc. Highlights of prescribing information: Besponsa™. Pfizer Inc.; 2017. Accessed Online July 30, 2024. https://labeling.pfizer.com/ShowLabeling.aspx?id=9503
European Medicines Agency. Summary of product characteristics: Besponsa. European Medicines Agency; 2017. Accessed Online July 30, 2024. https://www.ema.europa.eu/en/documents/overview/besponsa‐epar‐summary‐public_en.pdf
Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018;7(1):IJH02. doi:10.2217/ijh‐2017‐0023
Muller J, Obermeier I, Wohner M, et al. CD22 ligand‐binding and signaling domains reciprocally regulate B‐cell Ca2+ signaling. Proc Natl Acad Sci U S A. 2013;110(30):12402‐12407. doi:10.1073/pnas.1304888110
Clark EA, Giltiay NV. CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front Immunol. 2018;9:2235. doi:10.3389/fimmu.2018.02235
Jellusova J, Nitschke L. Regulation of B cell functions by the sialic acid‐binding receptors siglec‐G and CD22. Front Immunol. 2011;2:96. doi:10.3389/fimmu.2011.00096
Jin L, McLean PA, Neel BG, Wortis HH. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med. 2002;195(9):1199‐1205. doi:10.1084/jem.20011796
Schwartz‐Albiez R, Dorken B, Monner DA, Moldenhauer G. CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion. Int Immunol. 1991;3(7):623‐633. doi:10.1093/intimm/3.7.623
Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B‐cell acute lymphoblastic leukemia. Blood Adv. 2019;3(1):96‐104. doi:10.1182/bloodadvances.2018026211
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B‐cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93‐114. doi:10.1080/08820130500496878
DiJoseph JF, Popplewell A, Tickle S, et al. Antibody‐targeted chemotherapy of B‐cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother. 2005;54(1):11‐24. doi:10.1007/s00262‐004‐0572‐2
Walker S, Landovitz R, Ding WD, Ellestad GA, Kahne D. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci U S A. 1992;89(10):4608‐4612. doi:10.1073/pnas.89.10.4608
Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double‐stranded DNA site specifically. Science. 1988;240(4856):1198‐1201. doi:10.1126/science.3240341
Prokop A, Wrasidlo W, Lode H, et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase‐mediated mitochondrial amplification loop in an entirely Bax‐dependent manner. Oncogene. 2003;22(57):9107‐9120. doi:10.1038/sj.onc.1207196
Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti‐CD33 antibody‐calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47‐58. doi:10.1021/bc010021y
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B‐cell non‐Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085‐2093. doi:10.1200/jco.2009.25.1900
Goy A, Forero A, Wagner‐Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571‐581. doi:10.1111/bjh.14094
Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody‐based targeting agents for the treatment of non‐Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573‐583. doi:10.1200/jco.2012.42.7211
Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma. Br J Haematol. 2018;182(4):583‐586. doi:10.1111/bjh.14820
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22‐specific antibody‐targeted chemotherapy using inotuzumab ozogamicin (CMC‐544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240‐2245. doi:10.1038/sj.leu.2404866
Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti–CD22‐calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403‐411. doi:10.1016/s1470‐2045(11)70386‐2
Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728‐2736. doi:10.1002/cncr.28136
DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22‐positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167‐1180. doi:10.1182/bloodadvances.2016001925
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Cancer. 2019;125(14):2474‐2487. doi:10.1002/cncr.32116
DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81. doi:10.1038/s41408‐020‐00345‐8
Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE. Cancer. 2018;124(8):1722‐1732. doi:10.1002/cncr.31249
Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukaemia: a single‐arm, phase 2 study. Lancet Oncol. 2018;19(2):240‐248. doi:10.1016/s1470‐2045(18)30011‐1
Jabbour E, Short NJ, Senapati J, et al. Mini–hyper‐CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome‐negative B‐cell acute lymphocytic leukaemia: long‐term results of an open‐label phase 2 trial. Lancet Haematol. 2023;10(6):e433‐e444. doi:10.1016/s2352‐3026(23)00073‐x
Jabbour E, Short NJ, Jain N, et al. Hyper‐CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome‐negative B‐cell acute lymphocytic leukaemia: a single‐arm, single‐centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878‐e885. doi:10.1016/s2352‐3026(22)00285‐x
Short N, Jabbour E, Ravandi F, et al. The addition of inotuzumab ozogamicin to hyper‐CVAD plus blinatumomab further improves outcomes in patients with newly diagnosed B‐cell acute lymphoblastic leukemia: updated results from a phase II study [abstract]. Blood. 2022;140(supp 1):8966‐8968. doi:10.1182/blood‐2022‐157358
Nguyen D, Kantarjian HM, Short NJ, et al. Updated results from a phase II study of hyper‐CVAD, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B‐cell acute lymphoblastic leukemia [abstract]. Blood. 2023;142(supp 1):4245. doi:10.1182/blood‐2023‐190902
Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper‐CVD for patients with relapsed or refractory Philadelphia chromosome‐negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230‐234. doi:10.1001/jamaoncol.2017.2380
Garcia‐Manero G, Kantarjian HM. The hyper‐CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000;14(6):1381‐1396, x‐xi. doi:10.1016/s0889‐8588(05)70192‐1
Kantarjian H, Haddad FG, Jain N, et al. Results of salvage therapy with mini–hyper‐CVD and inotuzumab ozogamicin with or without blinatumomab in pre‐B acute lymphoblastic leukemia. J Hematol Oncol. 2023;16(1):44. doi:10.1186/s13045‐023‐01444‐2
Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836‐847. doi:10.1056/nejmoa1609783
Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):573‐579. doi:10.1182/asheducation‐2016.1.573
Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125(15):2579‐2586. doi:10.1002/cncr.32139
Stelljes M, Raffel S, Alakel N, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome‐negative B‐precursor ALL. J Clin Oncol. 2024;42(3):273‐282. doi:10.1200/jco.23.00546
Chevallier P, Leguay T, Kim R, et al. Fractionated inotuzumab ozogamicin combined with low‐intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)‐negative B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL‐INO study [abstract]. Blood. 2022;140(supp 1):6114‐6116. doi:10.1182/blood‐2022‐166035
Wieduwilt MJ, Yin J, Kour O, et al. Chemotherapy‐free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph‐negative, CD22‐positive, B‐cell acute lymphoblastic leukemia: Alliance A041703 [abstract]. J Clin Oncol. 2023;41(16 suppl):7006. doi:10.1200/jco.2023.41.16_suppl.7006
Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93(11):3983‐3993.
Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91(11):3995‐4019. doi:10.1182/blood.v91.11.3995.411a43_3995_4019
Igwe IJ, Yang D, Merchant A, et al. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre‐B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era—a Surveillance, Epidemiology, and End Results database analysis. Br J Haematol. 2017;179(4):618‐626. doi:10.1111/bjh.14953
Park HS. Current treatment strategies for Philadelphia chromosome‐positive adult acute lymphoblastic leukemia. Blood Res. 2020;55(S1):S32‐S36. doi:10.5045/br.2020.s006
Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96(8):1000‐1007. doi:10.1002/ajh.26238
Stock W, Martinelli G, Stelljes M, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome‐positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905‐913. doi:10.1002/cncr.33321
Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a US, single‐centre, single‐arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24‐e34. doi:10.1016/s2352‐3026(22)00319‐2
Foa R, Bassan R, Vitale A, et al. Dasatinib‐blinatumomab for Ph‐positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613‐1623. doi:10.1056/nejmoa2016272
Aldoss I, Advani AS. Have any strategies in Ph‐like ALL been shown to be effective? Best Pract Res Clin Haematol. 2021;34(1):101242. doi:10.1016/j.beha.2021.101242
Jabbour E, Roberts KG, Sasaki K, et al. Inotuzumab ozogamicin (Ino) may overcome the impact of Philadelphia chromosome (Ph)‐like phenotype in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2019;134(supp 1):1641. doi:10.1182/blood‐2019‐126940
Advani AS, Moseley A, Liedtke M, et al. SWOG 1312 final results: a phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/refractory CD22+ acute leukemia [abstract]. Blood. 2019;134(supp 1):227. doi:10.1182/blood‐2019‐125340
Dekker SE, Rea D, Cayuela JM, Arnhardt I, Leonard J, Heuser M. Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2023;43:e390010. doi:10.1200/edbk_390010
Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta‐analysis. JAMA Oncol. 2017;3(7):e170580. doi:10.1001/jamaoncol.2017.0580
Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522‐1531. doi:10.1182/blood‐2017‐08‐798322
Jabbour E, Gokbuget N, Advani A, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO‐VATE trial. Leuk Res. 2020;88:106283. doi:10.1016/j.leukres.2019.106283
Marconi G, Piciocchi A, Chiaretti S, et al. Gimema ALL2418: interim analysis of a phase IIa study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B‐cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation [abstract]. Blood. 2022;140(supp 1):6119‐6121. doi:10.1182/blood‐2022‐157937
Jabbour E, Haddad FG, Short NJ, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143(5):417‐421. doi:10.1182/blood.2023022330
DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatments is being answered. JCO Oncol Pract. 2022;18(7):479‐487. doi:10.1200/op.21.00843
Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720‐1729. doi:10.1016/j.bbmt.2019.04.020
Khouri IF, Alzahrani K, Kantarjian H, et al. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: a single‐center phase 1,2 trial. Am J Hematol. 2024;99(5):836‐843. doi:10.1002/ajh.27254
Metheny L, Sobecks RM, Cho C, et al. A multicenter study of posttransplant low‐dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8(6):1384‐1391. doi:10.1182/bloodadvances.2023011514
Wudhikarn K, King AC, Geyer MB, et al. Outcomes of relapsed B‐cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. Blood Adv. 2022;6(5):1432‐1443. doi:10.1182/bloodadvances.2021005978
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439‐448. doi:10.1056/nejmoa1709866
Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah(R) (tisagenlecleucel)—an overview of the clinical development journey of the first approved CAR‐T therapy. Hum Vaccin Immunother. 2023;19(1):2210046. doi:10.1080/21645515.2023.2210046
Frey NV. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood. 2022;140(1):11‐15. doi:10.1182/blood.2021014892
Shah BD, Ghobadi A, Oluwole OO, et al. KTE‐X19 for relapsed or refractory adult B‐cell acute lymphoblastic leukaemia: phase 2 results of the single‐arm, open‐label, multicentre ZUMA‐3 study. Lancet. 2021;398(10299):491‐502. doi:10.1016/s0140‐6736(21)01222‐8
Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor‐modified T‐cell therapy. Blood. 2017;130(21):2295‐2306. doi:10.1182/blood‐2017‐06‐793141
Park JH, Riviere I, Gonen M, et al. Long‐term follow‐up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449‐459. doi:10.1056/nejmoa1709919
Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3(suppl 1):39‐45. doi:10.1002/jha2.335
Shah BD, Cassaday RD, Park JH, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA‐3. J Immunother Cancer. 2023;11(8):e007118. doi:10.1136/jitc‐2023‐007118
Aldoss I, Roloff GW, Advani AS, et al. The impact of inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu‐cel) outcomes in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia (B‐ALL) [abstract]. Blood. 2023;142(supp 1):4877. doi:10.1182/blood‐2023‐182404
Kayser S, Sartor C, Luskin MR, et al. Outcome of relapsed or refractory acute B‐lymphoblastic leukemia patients and BCR‐ABL–positive blast cell crisis of B‐lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica. 2022;107(9):2064‐2071. doi:10.3324/haematol.2021.280433
Aldoss I, Otoukesh S, Zhang J, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022;128(3):529‐535. doi:10.1002/cncr.33967
Rubinstein JD, O'Brien MM. Inotuzumab ozogamicin in B‐cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol. 2023;14:1237738. doi:10.3389/fimmu.2023.1237738
Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO‐VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 2021;27(10):2742‐2754. doi:10.1158/1078‐0432.ccr‐20‐2399
Sartor C, Arpinati M, Chirumbolo G, et al. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after inotuzumab ozogamicin treatment. Hematol Oncol. 2022;40(4):734‐742. doi:10.1002/hon.3029
Wintering A, Ishiyama K, Tamaki S, et al. CD22low/Bcl‐2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2023;7(2):251‐255. doi:10.1182/bloodadvances.2021006810
Dalle JH, Giralt SA. Hepatic veno‐occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400‐409. doi:10.1016/j.bbmt.2015.09.024
Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310‐2314. doi:10.1182/blood.v99.7.2310
Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno‐occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578‐1582. doi:10.1182/blood‐2003‐01‐0255
Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open‐label, randomised, phase 3 INO‐VATE study. Lancet Haematol. 2017;4(8):e387‐e398. doi:10.1016/s2352‐3026(17)30103‐5
de Lima M, Kebriaei P, Lanza F, et al. P376: veno‐occlusive disease risk and other outcomes in patients with B‐cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin and proceeding to hematopoietic stem cell transplantation [abstract]. Hemasphere. 2023;7(suppl):e51811f0. doi:10.1097/01.hs9.0000968416.51811.f0
Kayser S, Sartor C, Giglio F, et al. Impact of inotuzumab ozogamicin on outcome in relapse or refractory acute B‐cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. Haematologica. 2024;109(5):1385‐1392. doi:10.3324/haematol.2023.284310
Özcan M, Cassaday RD, Singh P, et al. The efficacy and safety of low‐dose inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia: interim results of a phase 4 study [abstract]. Blood. 2021;138(supp 1):1208. doi:10.1182/blood‐2021‐150001
Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449‐456. doi:10.1038/s41409‐017‐0019‐y